



GOVERNMENT OF PAKISTAN
(CABINET DIVISION)
INTELLECTUAL PROPERTY ORGANIZATION
THE PATENT OFFICE
KARACHI



To,

Dated: 21-04-2009

Mr. Munir Ahmed,
Director (Admn.),
IPO-Pakistan,
Islamabad.

**Subject: WEEKLY NOTIFICATION OF PATENT OFFICE FOR THE
WEEKENDING 27-03-2009 TO BE PUBLISHED 22-04-2009 IN THE
GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No 18/IPO/2008/ RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

(Mrs. Yasmeen Abbasi)
Controller of Patents
Ph: 9215488

ENCL:

NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000

255/2009	<u>24-03-2009</u> DyStar Textilfarben GmbH & Co., Deutschland KG., Germany (Priority 25-03-2008 Germany)	“Azopyridone disperse dyes, their preparation and use”
256/2009	AstraZeneca AB, Sweden (Priority 26-03-2008 USA)	“Novel 5,7-disubstituted [1,3]thiazolo[4,5-D]pyrimidin-2-(3H)-one derivatives 258”
257/2009	Nestec S.A., Switzerland (Priority 28-03-2008 Europe)	“Probiotics for use in expecting female mammals for enhancing the immunity of their offsprings”
258/2009	F. Hoffmann-La Roche AG., Switzerland (Priority 24-02-1999 Europe) Divisional.	“4-phenyl-bridine compound”
259/2009	<u>25-03-2009</u> Celanese International Corporation, USA (Priority 27-03-2008 USA)	“Purification of acetic acid from wood acetylation process”
260/2009	Novartis AG, Switzerland (Priority 26-03-2008 USA)	“Hydroxamate-based inhibitors of deacetylases B”
261/2009	Takeda Pharmaceutical Company Limited, Japan (Priority 26-03-2008 Japan)	“Substituted pyrazole derivatives and use thereof”
262/2009	<u>26-03-2009</u> AstraZeneca AB, Sweden Array Biopharma, Inc., USA (Priority 28-03-2008 USA)	“Pharmaceutical composition 271”
263/2009	Nokia Siemens Networks Oy, Finland	“Enhanced finding of subscribers in communications system”

(Priority 31-03-2008 Europe)

264/2009	<u>27-03-2009</u> Merck & Co., Inc., USA (Priority 04-04-2008 USA)	“Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists”
265/2009	Basf SE, Germany (Priority 28-03-2008 USA)	“Pesticidal active mixtures comprising aminothiazoline compounds”
266/2009	Secret.	“Secret”
267/2009	Secret.	“Secret”
268/2009	Secret.	“Secret”
269/2009	Secret.	“Secret”
270/2009	ALE Airlight Energy SA, Switzerland (Priority 28-03-2008 Switzerland)	“Trough collector for a solar power plant”

APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.

360/1995	Novartis AG, Switzerland	Fungicidal composition containing metalaxyl, furalaxyl or benalaxyl and method for controlling fungus infestation”
----------	-----------------------------	--

AO1N 37/46, AO1N 43/08

140051

If the R-enantiomer of metalaxyl, furalaxyl or benalaxyl is used, this results in a markedly increased biodegradability of these plant fungicides in the soil and a higher activity on the plants, as compared with the data of the racemic active ingredients. Fungicidal compositions exhibiting said improved properties comprise either of these fungicides with a content of R-enantiomer of more than 70 per cent by weight based on the total amount of active ingredient.


1146/2000	F. Hoffmann-La Roche AG, Switzerland
-----------	--

“Substituted bisindolylmaleimide”

CO7D 209/04, A61K 31/404

140052

This invention relates to a Substituted bisindolylmaleimide disclosed are novel substituted pyrroles having the formula:



I.

This compound is suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. Also disclosed are pharmaceutical composition containing the foregoing compound and methods for the treatment and/or control of cancer.


736/2002 Bristol-Myers Squibb
Pharma Company,
USA.

“A lactam-containing compound as factor Xa inhibitor”

CO7D 207/26 223/10

140053

The present invention relates to a compound represented by formula (I):



(I).

Compound of the present invention is useful as inhibitor of trypsin-like serine proteases, specifically factor Xa.

399/2003 F. Hoffmann-La Roche AG, Switzerland
“Oral pharmaceutical composition containing ibandronate”
A61K 31/66,

140054

A pharmaceutical composition for the prevention or treatment of disorders due to pathologically increased bone resorption orally administered on one day per month, characterized that it comprises 100 or 150 mg ibandronic acid and one or more pharmaceutically acceptable excipients.

997/2004 Aventis Pharmaceuticals Inc., USA
“A substituted 1H-pyrrolo[3,2-b,3,2-c, and 2,3-c]pyridine-2-carboxamide compound as inhibitor of casein kinase I_E”
CO7D 401/04, A61K P25/00



140055

The present invention discloses and claims substituted 1H-pyrrolo[3,2-b]pyridine-2-carboxamides, 1H-pyrrolo[3,2-c]pyridine-2-carboxamides and 1H-pyrrolo[2,3-c]pyridine-2-carboxamides (compounds of formula (I)) as inhibitors of human casein kinase I_E, and methods of using said compounds of formula (I) for treating central nervous system diseases and disorders including mood disorders and sleep disorders. Pharmaceutical compositions comprising compounds of formula (I) and methods for the preparation of compounds of formula (I) are also disclosed and claimed.

349/2005 Bristol Myers Squibb Company, USA
“Pyridine compound”
CO7D 233/02

140056

The present invention is directed to compound having the formula



And methods for using them for the treatment of cancer.

926/2005 ENI S.P.A.
Italy
Enitecnologie S.p.A.,
Italy

“An apparatus for the atomization of a liquid stream by means of a gaseous dispersing stream”

BO1J 19/26,8/02, CO1B 3/38.

140057

Equipment for the atomisation of a liquid stream by means of a dispersing gaseous stream and for mixing the atomised product with a further suitable gaseous stream, characterized in that it comprises:

- a feeding zone (A) equipped with means suitable for feeding the liquid stream, the gaseous dispersing stream and further gaseous stream;
- one or more two-stage atomisation zones (N) of the liquid stream by means of the gaseous dispersing stream;
- a distribution zone (D) of the further gaseous stream; the first stage of the atomisation zone (N1) essentially consisting of a tubular core (2), through which the liquid stream passes, equipped with an appropriate series of nozzles (5), situated at the

same height, and an outer jacket (4) coaxial to said core, through which the gaseous dispersing stream passes, wherein said nozzles (5) allow the gaseous dispersing stream to enter the tubular core (2), perpendicularly to the axis of said tubular core (2), effecting a first atomisation of the liquid stream, the second stage of the atomisation zone (N2) essentially consisting of one or more nozzles (6) positioned at the end of the tubular core (2), parallel to the axis of said tubular core, to increase the atomisation degree, the distribution zone (D) essentially consisting of a further jacket (8), through which the further gaseous stream passes, external and coaxial to the jacket (4) of the first atomisation stage, and a series of nozzles (9) situated at the bottom of said further jacket, all positioned at the same height and parallel or inclined with an alpha angle lower than 40° with respect to the axis of the tubular core.




Fig. 1



613/2008 Bristol-Myers Squibb
Company,
USA

“Pharmaceutically acceptable salt of pyridine
compound”

CO7P 233/22, A61K 31/44

140058

The present invention is directed to the
pharmaceutically salt of compound having the
formual



and methods for using them for the treatment of
cancer.

639/2008 F. Hoffmann-La
Roche AG,
Switzerland

“A Pharmaceutical composition containing
ibandronate mono sodium salt mono hydrate”

A61K 31/66

140059

A pharmaceutical composition for the prevention or
treatment of disorders due to pathologically
increased bone resorption orally administered on
one day per month, characterized that it comprises
100 or 150 mg ibandronic acid in the for of
ibandronate mono sodium salt mono hydrate and
one or more pharmaceutically acceptable excipients.


934/2008 Bristol-Myers Squibb
Pharma Company,
USA

“A lactam-containing compound as factor Xa
inhibitor”


CO7D 207/26, 223/10

140060

The present invention relates to a compound selected from the group consisting of 1-(3-chlorophenyl)-7-oxo-6-[4-(2-oxo-1(2H)pyridinyl)phenyl]-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide; and 3-(1-hydroxy-1-methyl-ethyl)-1-(4-methoxy-phenyl)-6-[4-(2-oxo-2H-pyridin-1-yl)-phenyl]-1,4,5,6-tetrahydro-pyrazolo[3,3-c]pyridine-7-one. The compound is represented by the following formula



, or



, and

Is useful as inhibitor of trypsin-like serine proteases,
specifically factor Xa.


1006/2008 F. Hoffmann-La
Roche AG,
Switzerland

“A process for the preparation of substituted
bisindolylmaleimide”

CO7D 209/04, A61K 31/06

140061

This invention relates to a process for the preparation of novel substituted bisindolmaleimide having the formula:



I.

This compound and its pharmaceutically acceptable salts is suitable for administration to patients as continuous infusion solution and is useful in the treatment and/or control of cell proliferative disorders, in particular cancer. Also disclosed is pharmaceutical composition containing the foregoing compound and method for the treatment and/or control of cancer.

SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

139796	Merck & Co., Inc., USA	495/2003
139797	Syngenta Participations AG., Switzerland	1099/2003
139798	Sanofi-Aventis Deutschland GmbH., Germany	579/2006
139799	Merck & Co. Inc., USA	1140/2006

(MRS. YASMEEN ABBASI)
CONTROLLER OF PATENTS
Tel: 9215488